National burden and optimal vaccine policy for Japanese encephalitis virus in Bangladesh
Preprint
Abstract
Background Bangladesh first reported Japanese encephalitis virus (JEV) in 1977 and has seen regular cases since, however, no JEV vaccination program currently exists. A barrier to the use of JEV vaccines has been a limited understanding of the underlying burden. Methods We conducted a nationally representative serological community study in 70 communities in individuals of all ages (N=2,938, October 2015-January 2016). Serum samples were tested for IgG antibodies against JEV. We developed spatially explicit serocatalytic models to estimate the underlying force of infection across the country. We then used mathematical models to estimate the annual JE disease burden currently and under different vaccination strategies. Findings The overall JEV seroprevalence in Bangladesh was 3.4% (95%CI: 2.8–4.1, range 0–28% across communities). The annual probability of infection was 0.005 (95%CI: 0.003–0.009), with risk greatest near border regions. We estimated that annually there are 157 clinical cases (95%CI: 89-253) and 31 deaths (95%CI: 18-52). A vaccination strategy in the 10 most affected districts in 60% of 1–15 year olds would require 5 million doses and avert 1 case per 100,000 doses over five years compared to 35 million doses and 0.5 cases averted for a nationwide campaign. No vaccination scenario was cost-effective under a willingness-to-pay of three-times gross domestic product. Interpretation A spatially targeted vaccine campaign would be most effective in reducing JEV burden, however, would still not meet standard cost effectiveness targets. Funding CDCKeywords
This publication has 30 references indexed in Scilit:
- Individual, Household, and Community Drivers of Dengue Virus Infection Risk in Kamphaeng Phet Province, ThailandThe Journal of Infectious Diseases, 2022
- The SPDE approach for Gaussian and non-Gaussian fields: 10 years and still runningSpatial Statistics, 2022
- Hospital-based surveillance for Japanese encephalitis in Bangladesh, 2007–2016: Implications for introduction of immunizationInternational Journal of Infectious Diseases, 2020
- The overlooked dangers of anti-vaccination groups' social media presenceHuman Vaccines & Immunotherapeutics, 2017
- Disability weights for the Global Burden of Disease 2013 studyThe Lancet Global Health, 2015
- Restricted spatial regression in practice: geostatistical models, confounding, and robustness under model misspecificationEnvironmetrics, 2015
- Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier productVaccine, 2014
- Effectiveness of One Dose of SA 14-14-2 Vaccine against Japanese EncephalitisNew England Journal of Medicine, 2009
- Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case–control study in Nepalese children 5 years after immunizationVaccine, 2007
- Efficacy of single-dose SA 14–14–2 vaccine against Japanese encephalitis: a case control studyThe Lancet, 2001